Zobrazeno 1 - 10
of 2 140
pro vyhledávání: ''
Autor:
Alexis B. Cortot, Didier Debieuvre, L. Moreau, Radj Gervais, Jacques Margery, Julien Mazieres, Olivier Molinier, Michel Poudenx, Alexandra Langlais, Nicolas Girard, Patrick Dumont, Gérard Zalcman, Franck Morin, Virginie Westeel, Pierre-Jean Souquet, Eric Pichon, Fabrice Barlesi, Maurice Pérol, Jérôme Dauba, Jacques Cadranel, Clarisse Audigier-Valette, Denis Moro-Sibilot
Publikováno v:
Lung Cancer. 164:84-90
Benefit from maintenance in advanced non-squamous non-small cell lung cancer (NS-NSCLC) might favor switch maintenance after disease stabilization (SD) and continuation after objective response (OR). This trial assessed a maintenance strategy conditi
Autor:
María Elena Cabrera, Camila Peña, Pilar Leon, Vivianne Lois, Hernán Rojas, Valeska Vega, Alvaro Pizarro, Susana Calderon, Christine Rojas, Augusto Aspillaga, M. Luisa Gonzalez, Marvila Intriago, Bernardita Rojas, Cecilia Hales, Jacqueline Oliva, Mónica Romero, Marisa Capurro, Jorge J. Castillo
Publikováno v:
JCO Global Oncology.
PURPOSE Diffuse large B-cell lymphoma (DLBCL) is the most common lymphoma subtype. The purpose of this study was to evaluate the clinical features, prognostic factors, and results of DLBCL that was treated in the cancer centers of the public health s
Autor:
Ariadna Juarez-Garcia, John C O'Donnell, John R. Penrod, Mats Rosenlund, Simon Ekman, Jens Benn Sørensen, Anne Mette Kejs, Pia Horvat, L. Lacoin, Odd Terje Brustugun, Dony Patel, M. Daumont
Publikováno v:
Sørensen, J B, Horvat, P, Rosenlund, M, Kejs, A M, Patel, D, Juarez-Garcia, A, Lacoin, L, Daumont, M J, Penrod, J R, O'donnell, J C, Brustugun, O T & Ekman, S 2022, ' Initial treatment and survival in Danish patients diagnosed with non-small-cell lung cancer (2005-2015) : SCAN-LEAF study ', Future Oncology, vol. 18, no. 2, pp. 205-214 . https://doi.org/10.2217/fon-2021-0746
Aim: To describe initial treatment patterns and survival of patients diagnosed with non-small-cell lung cancer (NSCLC) in Denmark, before immune checkpoint inhibitor and later-generation tyrosine kinase inhibitor use. Patients & methods: Adults diagn
Autor:
Ziping Wang, Tienan Yi, Yun Fan, Guangqiang Zhao, Guangfa Wang, Gongyan Chen, Yong Song, Aimin Zang, Wenxiu Yao, Kangsheng Gu, Junfeng Liu, Caicun Zhou, Guohua Yu, Jianxing He, Jianling Bai, Huijuan Wang, Da Jiang, Xiaochun Zhang, Xiaohua Hu, Jie Zhang, Liyan Jiang, Kai Chen, Jiuwei Cui, Wenmin Xie, Qisen Guo, Lihong Wu, Chunhong Hu, Xiaorong Dong, Yueyin Pan, Junling Li, Guojun Zhang, Nong Yang, Min Peng, Xiaohong Wu, Lu Yue, Jianping Xiong, Qin Shi, Weihong Zhao, Yuping Li, Wei Tan
Publikováno v:
Cancer Communications, Vol 42, Iss 1, Pp 3-16 (2022)
Cancer Communications
Cancer Communications
Background Lipusu is the first commercialized liposomal formulation of paclitaxel and has demonstrated promising efficacy against locally advanced lung squamous cell carcinoma (LSCC) in a small‐scale study. Here, we conducted a multicenter, randomi
Publikováno v:
Journal of Cancer Research and Clinical Oncology
Purpose The objective of this study was to evaluate the safety and efficacy of immune checkpoint inhibitor (ICI) plus anlotinib as third-line treatment in extensive-stage small cell lung cancer (ES-SCLC). Methods A total of 120 patients with ES-SCLC
Autor:
Boris Kollárik, Michal Mego, Zuzana Sycova-Mila, Jozef Mardiak, Jan Slopovsky, Katarina Rejlekova, Michal Chovanec, Patrik Palacka, Jana Obertova
Publikováno v:
Anticancer Research. 41:5749-5759
BACKGROUND/AIM Systemic immune-inflammation index (SII) predicts survival of patients with various malignancies. This study explored the prognostic value of SII in metastatic urothelial carcinoma (MUC) subjects. PATIENTS AND METHODS We evaluated 181
Publikováno v:
Future Oncology. 17:4249-4261
While survival rates for patients with relapsed/refractory osteosarcoma are low, kinase inhibitors have shown efficacy in its treatment. The multikinase inhibitor lenvatinib, plus ifosfamide and etoposide, showed antitumor activity in a Phase II stud
Autor:
Seock-Ah Im, Jee Hyun Kim, Jin-Young Jang, Do-Youn Oh, Sae-Won Han, Yung-Jue Bang, Sung W. Ha, Sun Whe Kim, Jihyun Kwon, Eui Kyu Chie, Jae Sung Kim, Tae-You Kim, Kyung-Hun Lee
Publikováno v:
Cancer Research and Treatment : Official Journal of Korean Cancer Association
Purpose Despite curative resection, the 5-year survival for patients with resectable pancreatic cancer is less than 20%. Recurrence occurs both locally and at distant sites and effective multimodality adjuvant treatment is needed.Materials and Method
Autor:
Frederik Marmé, Helmut Forstbauer, Jens Huober, Gbg, Bruno Valentin Sinn, Michael Untch, Jenny Furlanetto, Christian Jackisch, Jens-Uwe Blohmer, Hans-Joachim Lück, Knut Engels, Ago-B, Grischa Wachsmann, Ekkehart Ladda, Nicole Burchardi, Elmar Stickeler, Sabine Schmatloch, Sibylle Loibl, Mattea Reinisch, Theresa Link, Volker Möbus, Carsten Denkert, Eva-Maria Grischke, Peter Klare, Marcus Schmidt, Christine Solbach, Andreas Schneeweiss, Julia Rey, Wolfgang Janni
Publikováno v:
European Journal of Cancer. 156:138-148
Background The GAIN-2 trial was designed to identify a superior intense dose-dense (idd) strategy for high-risk patients with early breast cancer. Here, we report an interim analysis, at which the predefined futility boundary was crossed. Patients an
Autor:
Shengmin Chen, Weifeng Wang, Huanliang Wu, Feng Yuan, Zhiren Lin, Gang Cheng, Shaohua Peng, Yunxiu Luo
Publikováno v:
Journal of Cancer Research and Clinical Oncology. 147:2913-2922
Assessing the downstaging effects of neoadjuvant chemotherapy (NACT) in patients with locally advanced nasopharyngeal carcinoma (LANPC) and predicting response to treatment remain challenging. The present study aimed to evaluate the long-term prognos